PHCRF (Healius) Short-Term Debt : $111 Mil (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Healius Short-Term Debt?

Healius's Short-Term Debt for the quarter that ended in Dec. 2024 was $111 Mil.

Healius's quarterly Short-Term Debt declined from Dec. 2023 ($176 Mil) to Jun. 2024 ($0 Mil) but then increased from Jun. 2024 ($0 Mil) to Dec. 2024 ($111 Mil).

Healius Short-Term Debt Historical Data

The historical data trend for Healius's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Healius Short-Term Debt Chart

Healius Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Short-Term Debt

Get a 7-Day Free Trial

6.56

4.28

Healius Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Short-Term Debt	Get a 7-Day Free Trial															134.82	-	176.17	-	110.96

Healius Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Healius Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Healius's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Healius Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Healius Ltd (OTCPK:PHCRF) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

PGZ:Germany HLS:Australia

Address

161 Castlereagh Street, Level 22, Sydney, NSW, AUS, 2000

Website

https://www.healius.com.au

Healius is Australia's second-largest pathology provider and third-largest diagnostic imaging provider, though the latter business is set to be sold in early 2025. Pathology and imaging revenue is almost entirely earned via the public health Medicare system. Healius typically earns approximately 75% of revenue from pathology and 25% from diagnostic imaging.